Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 32 articles: HTML format Text format

Single Articles

September 2018
1. WU B, Gu X, Zhang Q, Xie F, et al
   Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
   Oncologist. 2018 Sep 26. pii: theoncologist.2018-0150.
   PubMed     Text format     Abstract available
   
   
   August 2018
2. XIONG L, Li R, Sun J, Lou Y, et al
   Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
   Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120.
   PubMed     Text format     Abstract available
   
   
   
3. BUTTIGLIERO C, Shepherd FA, Barlesi F, Schwartz B, et al
   Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
   Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089.
   PubMed     Text format     Abstract available
   
   
   
4. XIE L, Nagpal S, Wakelee HA, Li G, et al
   Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
   Oncologist. 2018 Aug 20. pii: theoncologist.2018-0264.
   PubMed     Text format     Abstract available
   
   
   
5. SATO T, Soejima K, Fujisawa D, Takeuchi M, et al
   Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.
   Oncologist. 2018 Aug 17. pii: theoncologist.2017-0329.
   PubMed     Text format     Abstract available
   
   
   
6. RYSKA A, Buiga R, Fakirova A, Kern I, et al
   Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
   Oncologist. 2018 Aug 3. pii: theoncologist.2018-0008.
   PubMed     Text format     Abstract available
   
   
   
7. GREGORC V, Cavina R, Novello S, Grossi F, et al
   NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
   Oncologist. 2018 Aug 3. pii: theoncologist.2018-0292.
   PubMed     Text format     Abstract available
   
   
   
8. KAMATH SD, Kumthekar PU, Kruser TJ, Mohindra NA, et al
   Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.
   Oncologist. 2018 Aug 2. pii: theoncologist.2018-0022.
   PubMed     Text format     Abstract available
   
   
   June 2018
9. TOI Y, Sugawara S, Kawashima Y, Aiba T, et al
   Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
   Oncologist. 2018 Jun 22. pii: theoncologist.2017-0384.
   PubMed     Text format     Abstract available
   
   
   April 2018
10. CHABNER BA, Nabel CS
    Canakinumab and Lung Cancer: Intriguing, but Is It Real?
    Oncologist. 2018 Apr 17. pii: theoncologist.2018-0116.
    PubMed     Text format    
    
    
    
11. LABABEDE O, Meziane MA
    The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0659.
    PubMed     Text format     Abstract available
    
    
    
12. CHU CY, Choi J, Eaby-Sandy B, Langer CJ, et al
    Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0582.
    PubMed     Text format     Abstract available
    
    
    
13. AHLUWALIA MS, Becker K, Levy BP
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0572.
    PubMed     Text format     Abstract available
    
    
    March 2018
14. SAROCCHI M, Grossi F, Arboscello E, Bellodi A, et al
    Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Oncologist. 2018 Mar 22. pii: theoncologist.2017-0452.
    PubMed     Text format     Abstract available
    
    
    
15. SUH JH, Schrock AB, Johnson A, Lipson D, et al
    Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493.
    PubMed     Text format     Abstract available
    
    
    February 2018
16. MARRONE KA, Zhou X, Forde PM, Purtell M, et al
    A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465.
    PubMed     Text format     Abstract available
    
    
    
17. VON PAWEL J, Spigel DR, Ervin T, Losonczy G, et al
    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 7. pii: theoncologist.2017-0690.
    PubMed     Text format     Abstract available
    
    
    January 2018
18. KHOZIN S, Abernethy AP, Nussbaum NC, Zhi J, et al
    Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Oncologist. 2018 Jan 9. pii: theoncologist.2017-0353.
    PubMed     Text format     Abstract available
    
    
    December 2017
19. ODOGWU L, Mathieu L, Goldberg KB, Blumenthal GM, et al
    FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Oncologist. 2017 Dec 14. pii: theoncologist.2017-0425.
    PubMed     Text format     Abstract available
    
    
    
20. OGAWA A, Kondo K, Takei H, Fujisawa D, et al
    Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer.
    Oncologist. 2017 Dec 6. pii: theoncologist.2017-0187.
    PubMed     Text format     Abstract available
    
    
    September 2017
21. KUDERER NM, Poniewierski MS, Culakova E, Lyman GH, et al
    Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Oncologist. 2017 Sep 26. pii: theoncologist.2017-0205.
    PubMed     Text format     Abstract available
    
    
    August 2017
22. PAI-SCHERF L, Blumenthal GM, Li H, Subramaniam S, et al
    FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Oncologist. 2017 Aug 23. pii: theoncologist.2017-0078.
    PubMed     Text format     Abstract available
    
    
    
23. STINCHCOMBE TE
    Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2017 Aug 4. pii: theoncologist.2017-0204.
    PubMed     Text format     Abstract available
    
    
    July 2017
24. HAN Y, Zhang R, Lin G, Zhang K, et al
    Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.
    Oncologist. 2017 Jul 12. pii: theoncologist.2017-0042.
    PubMed     Text format     Abstract available
    
    
    May 2017
25. SCILLA KA, Bentzen SM, Lam VK, Mohindra P, et al
    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Oncologist. 2017 May 22. pii: theoncologist.2016-0443.
    PubMed     Text format     Abstract available
    
    
    
26. MIYAUCHI E, Inoue A, Usui K, Sugawara S, et al
    Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Oncologist. 2017 May 19. pii: theoncologist.2017-0059.
    PubMed     Text format     Abstract available
    
    
    
27. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Oncologist. 2017 May 15. pii: theoncologist.2016-0331.
    PubMed     Text format     Abstract available
    
    
    
28. BAIK CS, Myall NJ, Wakelee HA
    Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
    Oncologist. 2017 May 9. pii: theoncologist.2016-0458.
    PubMed     Text format     Abstract available
    
    
    April 2017
29. AGGARWAL C, Borghaei H
    Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    Oncologist. 2017 Apr 13. pii: theoncologist.2016-0345.
    PubMed     Text format     Abstract available
    
    
    
30. NISHIJIMA TF, Shachar SS, Nyrop KA, Muss HB, et al
    Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Oncologist. 2017;22:470-479.
    PubMed     Text format     Abstract available
    
    
    February 2017
31. WANG X, Wang X, Hodgson L, George SL, et al
    Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Oncologist. 2017;22:189-198.
    PubMed     Text format     Abstract available
    
    
    January 2017
32. BARSANTI-INNES B, Hey SP, Kimmelman J
    The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
    Oncologist. 2017;22:89-96.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: